Early Botox Improves Final Appearance in 'Split-Scar' Study
Early injections of botulinum toxin A can improve the final appearance of surgical scars, according to a study in the March issue of Plastic and Reconstructive Surgery®.
"This study demonstrates that early post-surgical botulinum toxin injections can produce better, narrower, and flatter facial surgical scars," according to the study by XiaoXi Lin, MD, PhD, and colleagues of Shanghai Jiao Tong University School of Medicine.
The results add to the growing list of clinical applications for BTX-A—beyond its cosmetic use in treating facial lines and wrinkles.
The study included 16 patients undergoing facial plastic and reconstructive surgery at the authors' department over a four-month period. The patients averaged 12 years of age. Most were undergoing surgery for some type of disfiguring facial birthmark, such as a melanocytic nevus or port wine stain.
In each patient, half of the facial scar was randomly assigned to treatment with BTX-A or inactive saline (placebo) solution, injected immediately at the end of surgery. Six months later, independent plastic surgeons made measurements and rated the appearance of both sides of the scar. The scars averaged 6.74 centimeters in length, with a range of three to 16 centimeters (about one to six inches). The study included follow-up data in 14 patients.
By several measures, the final appearance of the scar was significantly better on the half treated with BTX-A. On a 0- to 10-point scale (with 0 being worst and 10 being best), the surgeon's ratings for overall scar appearance averaged 5.76 on the half treated with BTX-A versus 4.97 on the placebo-treated half.
The BTX-A-treated sides were also lower and narrower than then comparison sides. Other scar characteristics (color, pliability, and vascularity) were not significantly different.
How does BTX-A affect the process of scar formation?
"Temporary muscular paralysis induced by BTX-A could decrease movement and stress around a healing wound," Dr. Lin and coauthors speculate. "This relief of tension may help prevent facial scar widening, hypertrophy and hyperpigmentation." They cite previous studies suggesting that BTX-A might also inhibit certain cells (fibroblasts) and mediators involved in scar.
The authors note some important limitations of their preliminary study, particularly the small number of patients included. They propose further studies comparing the effects of BTX-A on surgical scars with different injection techniques and in different locations on the face.
In a featured video on the Plastic and Reconstructive Surgery website, Editor-in-Chief Rod J. Rohrich, MD, notes that previous studies have reported the use of BTX-A to treat a variety of problems, "including chronic migraines, twitching eyelids, extreme sweating, crossed eyes, and more." He adds, "While more research is needed, this new [study] may demonstrate that early post-surgical injections of botulinum toxin can produce better, smaller, and flatter facial surgical scars."